National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 4 of 1993)

Overview

The National Health Act 1953 was enacted to establish a framework for national health services and benefits within Australia. One of the key gaps it was introduced to address was the need for a consistent and nationally coordinated approach to the provision of pharmaceutical benefits. This legislation aimed to ensure that the Australian public could access essential medicines and treatments in a manner that was equitable and financially sustainable. The policy objective of the Act, as outlined in the Pharmaceutical Benefits Declaration under Subsection 85(2AA), was to efficiently manage and update the list of drugs and medicinal preparations eligible for subsidy under the Pharmaceutical Benefits Scheme. This was achieved through the enacting authority of the Commonwealth Parliament, which authorised the Minister to delegate certain powers to the Assistant Secretary of the Pharmaceutical Benefits Branch. The Declaration, which came into effect on 1 April 1993, specified certain drugs such as Hexamine Mandelate, Phenethicillin Potassium, and Sodium Acid Citrate that would no longer be covered under Part VII of the National Health Act 1953, thereby streamlining the pharmaceutical benefits available to the public.

Scope and Application

The National Health Act 1953, as amended by the Declaration under Subsection 85 (2AA), applies to drugs and medicinal preparations listed in the Schedule, which are no longer subject to the provisions of Part VII of the Act. This legislative instrument specifically targets certain drugs, namely Hexamine Mandelate, Phenethicillin Potassium, and Sodium Acid Citrate, which cease to be covered under the Pharmaceutical Benefits Scheme as of 1 April 1993. The scope of the Act encompasses these particular pharmaceutical products, impacting entities and individuals involved in their manufacture, supply, or prescription within the Commonwealth of Australia. The Declaration, made by the Assistant Secretary of the Pharmaceutical Benefits Branch, Department of Health, Housing and Community Services, follows consultation with the Pharmaceutical Benefits Advisory Committee, ensuring a structured approach to the exclusion of these drugs from the national scheme. This decision is binding across the entire Commonwealth, affecting all relevant parties in accordance with the legislative provisions.

Key Provisions

The main operative sections of the declaration under subsection 85 (2AA) of the National Health Act 1953, as evidenced in this legislative instrument, concern the cessation of coverage for certain drugs and medicinal preparations under Part VII of the Act (subsection 85 (2AA)(2)). Specifically, the drugs Hexamine Mandelate, Phenethicillin Potassium, and Sodium Acid Citrate are named in the Schedule and are to be removed from the list of covered items under the Pharmaceutical Benefits Scheme (subsection 85 (2AA)(2)). The declaration comes into effect on 1 April 1993 (subsection 85 (2AA)(1)). The obligations and requirements imposed by this Act pertain to the cessation of coverage for the specified drugs. The Assistant Secretary, Pharmaceutical Benefits Branch, in this instance David Trevor Graham, is tasked with making this declaration following advice from the Pharmaceutical Benefits Advisory Committee (subsection 85 (2AB)). This ensures that the decision to remove the drugs from coverage is based on informed and expert advice. The Act also mandates that the declaration be dated and signed by the relevant authority, in this case David Trevor Graham, to formalise the decision and provide clarity on the authority behind the changes (subsection 85 (2AA)(4)). In terms of consequences for breach, the Act does not explicitly detail specific offences or penalties within the text provided. However, failure to adhere to the requirements and obligations of the Act, such as not following the proper advisory and declaration processes, could potentially lead to administrative or legal repercussions. The severity of these repercussions would depend on the specific nature of the breach and could range from corrective actions to more serious legal consequences depending on the context and impact of the non-compliance.